NLS VPAC1

Drug Profile

NLS VPAC1

Alternative Names: 64Cu-TP-3805; Cu64-NLS-VPAC1; Cu64-TP 3805; Ga68-NLS-VPAC1; NLS-VPAC1; TP3805

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Thomas Jefferson University
  • Developer National Institutes of Health (USA); Naviscan PET Systems; NuView Life Sciences; Thomas Jefferson University
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Thomas Jefferson University and the National Institutes of Health initiate a phase I trial for Prostate cancer (Diagnosis) in USA (IV) (NCT02989623)
  • 01 Jun 2015 Thomas Jefferson University and the National Institutes of Health complete a phase I trial in Prostate cancer (Diagnosis) in USA (IV) (NCT02603965)
  • 29 Jul 2013 Phase-I clinical trials in Diagnostic imaging in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top